2 Top Value Stocks to Buy Right Now on Sale

Despite the TSX’s continuing rally, bargain deals are available to value investors. Trillium Therapeutics stock and Bausch Health stock are well positioned for a breakout and should increase in value in 2021 and beyond.

| More on:

The S&P/TSX Composite continues its incredible rally from a pandemic-ravaged economy in 2020. Despite the substantial gains, investors can find hidden gems or value stocks the market is underestimating. You can buy a couple of them at discounted prices and reap the rewards in the medium or long term.

TSX’s healthcare sector experienced a broad weakness that it was one of the worst performers last year. However, it has regained lost ground and is now the second-best performing sector with a 27.65% year-to-date gain. Among the bargain deals today are Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) and Bausch Health (TSX:BHC)(NYSE:BHC).

Transformation program

Trillium Therapeutics trades at $11.81 per share, 37% off its 2020 year-end closing. This value stock was the bright spot in the healthcare space last year with its 1,308% total return. The current share price is a good entry point before it soars again. Analysts forecast the stock to climb to $21 or a 78% return potential.

The $1.22 billion clinical-stage immuno-oncology company from Mississauga develops therapies for cancer treatment. Like most biotech firms, Trillium’s growth hinges on successful clinic trials of its lead drug candidates. The company’s two clinical programs, TTI-621 and TTI-622, focuses on CD47 that cancer cells or tumours frequently use to evade the immune system.

In Q1 2021 (quarter ended March 31, 2020), Trillium reported a $10.8 million net loss versus the $16.6 million net loss in Q1 2020. The research and development expenses grew to $5.9 million due mainly to higher manufacturing costs. Trillium had to support its expanded clinical operations and higher clinical trial costs related to increased patient enrollment.

Jan Skvarka, Trillium’s president and CEO, said, “Building on a robust foundation anchored in a demonstrated monotherapy proof of concept of TTI-622 and TTI-621 in multiple lymphoma indications. We have initiated an ambitious Phase 1b/2 program in nine patient settings across hematologic and solid tumor cancers.”

Skvarka is confident Trillium is well positioned to execute its recently initiated Phase 1b/2 program with a major transformation program. It should generate a robust flow of new data over the next couple of years.

Innovation in eye health

Bausch Health was an underperformer, if not the worst in the sector last year with its -32% total return. However, the stock ($31.82 per share) is among the actively traded equities today. The year-to-date gain is nearly 47%, notwithstanding the $610 million net loss in Q1 2021 (quarter ended March 31, 2021).

However, the $11.47 billion firm from Laval generated $443 million cash from operations, nearly 70% more than in the same period last year. Bausch engages in the manufactures of pharmaceutical, medical device, and over-the-counter (OTC) products. The primary focus is on eye health, gastroenterology, and dermatology.

The thing to watch for is the next generation of Bausch + Lomb eyeTELLIGENCE software. Bausch and Lochan LLC, a software development company, will collaborate to develop the clinical decision support software and launch its first phase by 2022.

Bausch will become the first company to connect the operating room to the cloud using eyeTELLIGENCE technology. According to Dr. Mark Lobanoff, founder of Lochan, the next generation of eyeTELLIGENCE software will help surgeons use data to make faster treatment and procedural decisions.

Must-buys

Value investors should include Trillium Therapeutics and Bausch Health in their shopping lists. The respective share prices could soar in 2021 and beyond.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies.

More on Investing

A data center engineer works on a laptop at a server farm.
Tech Stocks

3 No-Brainer Data Centre Stocks to Buy With $500 Right Now

Data centres are going to be a huge growth opportunity in the next decade. And these are the top buys.

Read more »

Paper Canadian currency of various denominations
Bank Stocks

1 Magnificent Canadian Dividend Stock Down 28% to Buy and Hold for Decades

This top Canadian dividend stock is underperforming its large peers this year, but a turnaround could be on the horizon.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

Where to Invest Your $7,000 TFSA Contribution

The TFSA is attractive for investors who want to generate tax-free passive income.

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Dividend Stocks

TFSA Investors: 3 Dividend Stocks Worth Holding Forever

These TSX stocks have the potential to grow their dividends over the next decade, making them top investments for TFSA…

Read more »

hand stacks coins
Investing

Secure a Wealthy Future With These 3 Canadian Stocks

These Canadian stocks have the potential to appreciate substantially over time and may also enhance returns through dividend payments.

Read more »

Tractor spraying a field of wheat
Dividend Stocks

Is Nutrien Stock a Buy for its Dividend Yield?

Nutrien is down more than 50% form the 2022 highs. Is NTR stock now oversold?

Read more »

analyze data
Investing

3 Blue-Chip Stocks Every Canadian Should Own

These blue-chip stocks are backed by large-cap companies with well-established businesses, solid fundamentals, and a growing earnings base.

Read more »

dividends grow over time
Stocks for Beginners

The Smartest Growth Stock to Buy With $2,000 Right Now

Do you have $2,000 to invest for the long term? These three TSX stocks have and will continue to deliver…

Read more »